Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study

BACKGROUND: Deficiency of phenylalanine hydroxylase causes phenylketonuria (PKU) with elevated phenylalanine (Phe) levels and associated neuropsychiatric and neurocognitive symptoms. Pegvaliase (PEGylated phenylalanine ammonia lyase) is an investigational agent to lower plasma Phe in adults with PKU...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo, Nicola, Zori, Roberto, Wasserstein, Melissa P., Vockley, Jerry, Burton, Barbara K., Decker, Celeste, Li, Mingjin, Lau, Kelly, Jiang, Joy, Larimore, Kevin, Thomas, Janet A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031112/
https://www.ncbi.nlm.nih.gov/pubmed/29973227
http://dx.doi.org/10.1186/s13023-018-0858-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031112/
https://www.ncbi.nlm.nih.gov/pubmed/29973227
http://dx.doi.org/10.1186/s13023-018-0858-7

Ejemplares similares